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Table 1   Formulation, size and zeta-potential of liposome, Oct-targeted liposomes and PEGylated liposome loaded 
with CPT-11  
Liposome formulation: DSPC?cholesterol at a molar ratio of 55?45 and Oct-PEG3400-DSPE or PEG2000-DSPE. 









 1.0 ± 1.5- 5.5 ±9.151 0 0 LC
0.25Oct-CL 0.25 0 141.3 ± 6.1 -11.2 ± 3.5 
0.8Oct-CL 0.8 0 141.6 ± 9.4 -17.8 ± 6.9 
1.0Oct-CL 1.0 0 153.9 ± 6.2 -18.1 ± 4.3 
1.2Oct-CL 1.2 0 134.2 ± 5.4 -15.3 ± 1.9 
1.4Oct-CL 1.4 0 147.6 ± 2.4 -17.3 ± 4.7 
1.6Oct-CL 1.6 0 136.6 ± 3.2 -19.5 ± 1.3 


















Figure. 1. Chemical structure of Oct-PEG3400-DSPE
(MW??5,200)
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Figure. 2. Effect of Oct surface density of Oct-CL on
cellular association
DXR-loaded liposomes modified with various Oct-PEG-
DSPE concentrations (mol?) were incubated with TT
cells at 50?g/ ml DXR for 2 h at 37?. Each value rep-
resents the mean ? S.D. (n = 3). * Differences are sta-
tistically significant from SL at P < 0.05.
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Figure. 3. Scheme (A) and DXR fluorescence (B) of
cellular association of 1.6Oct-CL loaded with DXR
with TT cells in the presence of two excess vol-
umes of empty 1.6Oct-CL (i) or empty SL (ii) for
2 h at 37? by flow cytometry
Each value is the mean ? S.D. for three experiments.











































































Figure. 4. Cytotoxicity of free Oct, empty SL or
empty 1.6Oct-CL on TT cells in the presence or
absence of 1.5?M CPT-11
TT cells were treated with empty Oct-CL (A), empty SL
(B) and free Oct (C), alone or combined with CPT-11.
Each value represents the mean ? S.D. (n = 4). * P <
0.05 versus “Control” (cell viability of un-treatment). # P
< 0.05 versus CPT-11 alone.
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Table 2    IC50 of free CPT-11 and liposomes loaded with CPT-11 on TT cells after various incubation times  
 
 
Note; Mean ± S.D. (n = 4). ∗, Differences are statistically significant from SL at P < 0.05. 
Formulation IC50 (μM) 
 h 69 h 27 h 84 
Free CPT-11 7.43 ± 6.73 5.10 ± 1.85 3.76 ± 0.61 
1.6Oct-CL 29.05 ± 19.40 8.72 ± 1.14 1.05 ± 0.47* 


































Figure. 5. Effects of empty SL or empty 1.6Oct-CL
on Akt-TSC2-p70S6K in TT cells (A) and TT tumor
tissue (B)
TT cells were treated with empty Oct-CL (correspond to
0.42?M of Oct-PEG-DSPE), empty SL liposomes modi-
fied with 0.42?M PEG-DSPE, CPT-11 (13?M) or SN-
38 (0.14?M) for 24 h. TT tumor-bearing mice were in-
jected with empty Oct-CL 24 h before the experiment
Table 2. IC50 of free CPT-11 and liposomes loaded with CPT-11 on TT cells after various incubation
times
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Figure. 6. Biodistribution of liposomal CPT-11
(1.6Oct-CL and SL) at 6 h or 24 h after a single in-
jection into mice bearing TT tumor
Frozen sections of tumors were observed using a fluo-
rescence microscope (A), tissues biodistribution of CPT-
11 (B), and SN-38 (C). Each value represents the mean
? S.D. (n = 3). * P < 0.05, and ** P < 0.01 versus SL.
































Figure. 7. CPT-11 converted by carboxylesterase ac-
tivity in homogenates of liver and TT tumor
Cytosol was incubated with CPT-11 at 37? for 1 h.
Each value represents the mean ? S.D. (n = 3).
* P < 0.05.
???? ??ILS? ??ILS = ?T/C - 1? x 100??
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)  Survival time (d) 
 Median (N) %ILS 
Saline 68 (4) 0.0 
Free CPT-11 88 (4) 30.4 
CL 103 (4) 52.6 
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1.6 Oct-CL (10 mg CPT-11/kg x 2) 
free CPT-11 (30 mg CPT-11/kg x 3)
Saline
Figure. 8. Effect of Oct-modification of liposomal
CPT-11 on antitumor activity in mice bearing TT
tumor
Antitumor activity of 1.6Oct-CL was compared to that
of CL or free drug. Liposomal CPT-11 (? : 10 mg/kg
Oct-CL, ?: 10 mg/kg CL) was injected intravenously on
days 24 and 27, and free CPT-11 (? : 30 mg/kg) and sa-
line (?) were injected three times. Arrows indicate the
day of drug injections. Each value represents the mean
? S.D. (n = 4). * Differences are statistically signifi-

































































Figure. 9. Therapeutic efficacy of intravenous injec-
tion of 1.6Oct-CL or SL in mice bearing TT tumor
Treatment effects of liposomal CPT-11 on tumor size
(A), body weight (B), and survival rate (C). The formu-
lations used were Oct-CL (?), SL (?) and saline (?).
Each value represents the mean ? S.D. (n = 6). * P <
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Figure. 10. Therapeutic efficacy of intravenous in-
jection of empty 1.6Oct-CL or empty SL in mice
bearing TT tumor
Treatment effects of empty liposomes on tumor size (A),
body weight (B). The formulations used were empty
Oct-CL (?), empty SL (?) and saline (?). Each value
represents the mean ? S.D. (n = 6).
O t CL (CPT 11)c -  -
Figure. 11. Proposed mechanisms of antitumor ef-
fects of Oct-CL for MTC
? ? ? ?
1) Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P. Current approaches and perspectives in
the therapy of medullary thyroid carcinoma. Cancer. 2001;91:1797-808.
2) Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 dif-
ferentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol
Metab. 2001;86:2161-9.
3) Zatelli MC, Tagliati F, Taylor JE, Piccin D, Culler MD, degli Uberti EC. Somatostatin, but not somatostatin receptor
subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thy-
roid carcinoma cell line, TT. Horm Metab Res. 2002;34:229-33.
4) Mato E, Matías-Guiu X, Chico A, Webb SM, Cabezas R, Berná L, et al. Somatostatin and somatostatin receptor sub-
type gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:2417-20.
5) Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, et al. Development of the polymer
micelle carrier system for doxorubicin. J Control Release. 2001;74:295-302.
6) Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, et al. Activity of irinotecan and the tyrosine
kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab. 2006;91:79-84.
7) Koga K, Hattori Y, Komori M, Narishima R, Yamasaki M, Hakoshima M, et al. Combination of RET siRNA and
irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci.
2010.
8) Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: a new
derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990;8:1907-12.
9) Willis M, Forssen E. Ligand-targeted liposomes. Adv Drug Deliv Rev. 1998;29:249-71.
10) Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S, Allen TM. Targeted delivery and triggered release of liposomal
doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta. 2001;1515:144-58.
Proc? Hoshi Univ. No.54, 2012
? ?? ?
11) Harrington KJ, Syrigos KN, Vile RG. Liposomally targeted cytotoxic drugs for the treatment of cancer. J Pharm
Pharmacol. 2002;54:1573-600.
12) Wang CY, Huang L. pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of
a foreign gene in mouse. Proc Natl Acad Sci U S A. 1987;84:7851-5.
13) Curiel DT, Agarwal S, Wagner E, Cotten M. Adenovirus enhancement of transferrin-polylysine-mediated gene deliv-
ery. Proc Natl Acad Sci U S A. 1991;88:8850-4.
14) Barratt G, Tenu JP, Yapo A, Petit JF. Preparation and characterisation of liposomes containing mannosylated
phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta. 1986;862:153-64.
15) Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers. 2002;66:161-83.
16) Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of
neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer. 2008;15:701-20.
17) Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Disposition of sandostatin, a new synthetic
somatostatin analogue, in rats. Drug Metab Dispos. 1989;17:699-703.
18) Kutz K, Nüesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol
Suppl. 1986;119:65-72.
19) Bakker WH, Krenning EP, Breeman WA, Kooij PP, Reubi JC, Koper JW, et al. In vivo use of a radioiodinated
somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl
Med. 1991;32:1184-9.
20) Froidevaux S, Heppeler A, Eberle AN, Meier AM, H?usler M, Beglinger C, et al. Preclinical comparison in AR4-2J
tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs
for tumor diagnosis and internal radiotherapy. Endocrinology. 2000;141:3304-12.
21) Smith-Jones PM, Stolz B, Albert R, Ruser G, Briner U, Mäcke HR, et al. Synthesis and characterisation of [90Y]-Bz-
DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours. Nucl
Med Biol. 1998;25:181-8.
22) Oberg K. Cancer: antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol. 2010;6(4):188-9.
23) Chua YJ, Michael M, Zalcberg JR, Hicks RJ, Goldstein D, Liauw W, et al. Antitumor effect of somatostatin analogs
in neuroendocrine tumors. J Clin Oncol. 2010;28(3):e41-2; author reply e3-4.
24) Weckbecker G, Raulf F, Tolcsvai L, Bruns C. Potentiation of the anti-proliferative effects of anti-cancer drugs by
octreotide in vitro and in vivo. Digestion. 1996;57 Suppl 1:22-8.
25) Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for
neuroendocrine differentiation of prostate cancer. J Biol Chem. 2007;282:3571-83.
26) Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-30.
27) Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, et al. Antitumor efficacy of intermit-
tent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal
protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004;64:252-61.
28) Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K. Antitumor activity of a camptothecin de-
rivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol. 1991;28:192-8.
29) Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin de-
rivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-91.
30) Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Frétigny E, et al. CPT-11 converting carboxylesterase
and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer. 1999;80:364-70.
Proc? Hoshi Univ. No.54, 2012
? ?? ?
Octreotide-targeted liposomes loaded with CPT-11 for the treatment of medullary thyroid carcinoma
Yuko IWASE
Fine Drug Targeting Research Laboratory, Institute of Medicinal Chemistry, Hoshi University
Medullary thyroid carcinoma (MTC) is a rare endocrine tumor, which shows overexpress somatostatin receptor sub-
type 2. There is no systemic therapy for MTC. Octreotide (Oct) is a somatostatin analog that has a high binding affinity
for somatostatin receptor and can be used as a tumor-targeting ligand. In this study, we prepared Oct-targeted liposomes
loaded with irinotecan and evaluated the therapeutic efficacy of the liposome for MTC. Oct-targeted liposomes loaded
with irinotecan significantly suppressed the tumor-growth of SSTR-positive human MTC cell line TT xenografts, and im-
proved the median survival of the liposome-treated mice compared with PEGylated liposome-treated mice. Furthermore,
empty Oct-targeted liposome, which was loaded with no drug, inhibited the phosphorylation of p70S6K in vitro and in
vivo. These findings indicated that Oct-targeted liposome loaded with CPT-11 has dual functions with targeted tumor de-
livery and assistance of cellular cytotoxicity for MTC.
